


Xenitra[®]

Investor Presentation

May 2026



Disclaimer



The information contained in this presentation has been prepared by Xenitra Limited ACN 150 110 017 (Company).

This presentation contains summary information about the current activities of the Company and its subsidiaries as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be complete or to provide all information that an investor should consider when making an investment decision. It should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange. Certain market and industry data used in connection with this presentation has been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither the Company nor its representatives have independently verified any such data provided by third parties.

This presentation is not an offer, invitation, solicitation or other recommendation with respect to the subscription for, purchase or sale of any securities in the Company. This presentation has been made available for information purposes only and does not constitute a prospectus, short form prospectus, profile statement, offer information statement or other offering document under Australian law or any other law. This presentation is not subject to the disclosure requirements affecting disclosure documents under Chapter 6D of the Corporations Act 2001 (Cth) and does contain all the information which would be required in such a disclosure document or prospectus.

This presentation is not a financial product nor investment advice nor a recommendation to acquire shares and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek legal and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide, and this presentation does not constitute the provision of, financial product advice in respect of the Company's shares.

The information in this presentation may be changed, modified or amended at any time by the Company, and is not intended to, and does not, constitute representations or warranties of the Company. Neither the Company or any of its directors, officers, agents, employees or advisors give any representation or warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Accordingly, to the maximum extent permitted by law, none of the Company, its directors, employees or agents, advisers, nor any other person accepts any liability whether direct or indirect, express or limited, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the information or for any of the opinions contained in this presentation or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this presentation.

This presentation may contain certain "forward looking statements". Forward risks, uncertainties and other factors, many of which are outside the control of the Company can cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise such statements. Investors are cautioned that any forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in any forward-looking statements made.

An investment in the Company's shares is subject to investment and other known and unknown risks, some of which are beyond the control of the Company. Such risks and uncertainties include, but are not limited to: the impact of Covid-19, the acquisition and retention of customers, third party service provider and/or platform provider reliance, competition, reliance on key personnel, additional requirements for capital, the ability to raise sufficient funds to meet the needs of the Company in the future, potential acquisitions, platform integration, platform disruption, commercialisation, changes in technology, new products, development timeframes, product distribution, insurance, security breaches, maintenance of key business partner relationships, management of growth, brand establishment and maintenance, as well as political and operational risks, and governmental regulation and change in laws. Additional risks and uncertainties that the Company is unaware of, or that it currently considers to be immaterial, may also become important factors that adversely affect the Company's operating and financial performance.

Before investing in the Company, you should consider whether this investment is suitable for you. Potential investors should consider publicly available information on the Company, carefully consider their personal circumstances and consult their professional advisers before making an investment decision.

This release has been approved by the Chairman of the Board of Directors (Xenitra Limited).

Growing the world's
best brands in Asia
with *authentic*
products and scaling
with *loyal customers*



Xenitra[®]

Xenitra® Corporate Snapshot

Top 20 Holders: 58%

Share Price: 0.4c

Market Cap: \$15m

CAPITAL STRUCTURE

Fully Paid Ordinary Shares

3,862,858,827 (3,178 holders)

Listed Options @ \$0.010 exp 23/10/26

1,036,285,358 (83 holders)

Unlisted Options @ \$0.015 exp 30/11/26

15,000,000 (1 holders)

Unlisted Options @ \$0.004 exp various dates (12/12/26-01/10/30)*

948,500,000 (57 Holders)

TOTAL: 5,862,644,185 (3,294 holders)

\$70m+

Total Sales since 2024

200+

Online Storefronts

25+

Brand Partners

50+

RWA-Tokenised Distributors

A new name. A new chapter.

AuMake Limited officially rebrands
to Xenitra Limited on the ASX.

ASX: XEN

Formerly: AuMake Limited (ASX: AUK)



ASX : XEN

The rebrand explained

Xenitra reflects the company's modernised vision – connecting premium Global FMCG Brands with high-growth Asian consumer markets. Our growth strategy is based on three product-tailored sales channels: Nutritional product trading, Online and Hospital OTC Medicine Sales and Real World Tokenised Sales of Exclusive Brands.

What's new

- Name: Xenitra Limited
- ASX code: XEN
- New brand identity & strategy
- A more focused FMCG mandate:
 - High velocity nutritionals,
 - Nutraceuticals,
 - OTC Medicines,
 - Household and Personal Care
- Real World Asset Tokenisation Sales Ecosystem through a blockchain-enabled ecommerce layer


Xenitra®



Xenitra has earned some crucial insights by creating & operating a \$70m+ trusted Asian sales ecosystem for international brands allowing us to expand into the exciting new segments of OTC Medicine and RWA-Tokenisation.

Brands in our ecosystem now

NUTRICIA
OVER 100 YEARS
OF CARING FOR BABIES



Xenitra has now focused
on three core segments
in our growth strategy;

- Nutritional
- OTC Medicine
- Real World Asset (RWA) Tokenisation





Nutritionals

Summary

The evolution of the historical daigou based selling model that has evolved across online platforms and into B2B channels

Product Profile

Functional and Medical Foods, such as infant formula and Vitamin Mineral and Supplement (VMS) category products from leading brands

Margin Profile

3-5%

Future Focus

Consolidated now under leaner structure, growth with a focus on B2B channels, such as via the \$30m Rockcheck partnership



OTC Medicine

Summary

New channel that is opening due to regulatory relaxation in China, driven by core online platform sales and B2B sales into Chinese Hospitals

Product Profile

Over the Counter (non-prescription) small molecule medicines, structure function benefit Complementary Medicines

Margin Profile

20-40%

Future Focus

Develop and expand the online sales channel execution while building new brand partnerships, explore generic "own brand" as demand and velocity increase



RWA Tokenisation

Summary

Blockchain enabled closed sales ecosystem leveraging existing online and B2B sales channels for products sold exclusively in China by Xenitron, supported by authentication and loyalty / rewards program driving willingness to pay in customers

Product Profile

FMCG products across all categories exclusive to Xenitron

Margin Profile

40% -90%

Future Focus

Rapidly expanding sales by onboarding new brands and increasing numbers of new distributor and end user customers

Nutritionals Business
has been revitalised



Xenitra®



Q3 sales jump 300% quarter-on-quarter.

Preliminary unaudited results confirm strongest quarter since restructuring began.

\$8.3m

Q3 total sales

+300%

QoQ growth vs Q2

\$4m+

March sales alone

\$70m+

Lifetime sales since 2024

Full sales recovery to historical highs

Nutritionals drove the Q3 lift across B2B wholesale, retail distribution, and major e-commerce platforms. March sales alone exceeded \$4m – bringing annualised run-rate beyond the FY24 levels.

Leaner structure

A stronger focus on larger B2B customers feeding B2C channels and a refocused, leaner operating structure following a full year of business restructuring means the contribution margins for the business unit are significantly improved compared to hist

New channels ahead

OTC Medicines (via Fukang acquisition) and OPAL Tokenised sales were not yet contributing to Q3. Both flagged to begin delivering revenue from Q4 onwards, at significantly higher gross margins.

\$30m Danone partnership with Rockcheck Group.

Two agreements formalise and significantly expand Xenitra's most important B2B relationship.

1 Danone Product Sales Agreement

- Targets ~\$30m AUD (140m RMB) in Danone product sales to Rockcheck over 12 months.
- Period: 1 May 2026 – 30 April 2027. Option to extend for a further 3 years subject to Q1 performance.
- Xenitra–Rockcheck relationship active since 2023. FY26 sales to date already exceed \$10m AUD.

2 Authorised Supplier Framework Agreement

- Establishes Xenitra's Australian subsidiary as an authorised supplier to the Rockcheck Group.
- Enables brand partners to have products procured directly in Australia for B2B sales into Rockcheck companies.
- Scope to add further product lines beyond Danone in the future.

Deal at a Glance

\$30m

AUD revenue target

140m

RMB equivalent

12

month initial term

+3yr

extension option

\$10m+

FY26 sales to date

2023

Partnership since

Xenitra®

Cross Border
OTC Medicine

The next big thing



Fukang Trading Acquisition

OTC medicines channel now operational



Hong Kong Fukang Trading Co. acquired for ~A\$100,000 enabling a fast start into the ecommerce channel with established sales, warehousing and team members experienced in cross border OTC Medicine Sales in Greater China.

A significant new growth opportunity in China

Online sales of OTC Medicines to consumers in China are now allowed through Hong Kong and have the potential to far out pace the historical infant formula nutritional market's growth

HK Pharma License has been acquired

Following wholesale license approval, Xenitra now holds a Hong Kong pharmaceutical wholesale license that enables cross-border OTC sales into China (and prescription drug wholesale)

JD.com Storefront

The company has acquired an active OTC Medicine shopfront on JD.com, China's major B2C e-commerce platform allowing for an immediate and seamless commencement of sales

Trademark and Warehouse infrastructure

Class 35 trademark registration plus warehouse logistics service, customer database, and on-hand inventory also acquired

Key Leadership Team

The acquisition brings with it an experienced local Hong Kong team, that is supercharged by the recruitment of a high-powered General Manager with direct platform experience

Expanding Brand Partnerships

The company is in advanced discussions with leading OTC and Generic OTC brand owners and master distributors to build the online offering tailored to China consumer demand

RWA Tokenisation

*Real products,
Real consumers,
Real-world assets
— tokenised*



Xenitra[®]

OPAL Token Ecosystem

Xenitra[®]

Product tokenisation

PROCUREMENT

Contracted offtake secured directly from brand owner by XEN under agreed supply terms.

REVENUE MODEL

Tokenised products sold by XEN at high margin, generating the capital base for the reserve.

XEN distributes and tokenises products (e.g. EZZ)

Token issuance

CUSTOMER ALLOCATION

OPAL Tokens issued automatically to each customer purchasing qualifying XEN products.

RESERVE FUNDING

A portion of each sale margin is allocated to the OPAL Token Reserve at every transaction.

OPAL Tokens tethered to products at point of sale

Token redemption

REDEMPTION MECHANISM

Customers redeem tokens via the XENSHOP; tokens are permanently burned at point of redemption.

INVENTORY & BENEFITS

Rewards inventory and member benefits are funded directly through the Token Reserve.

Tokens 'burned' in the XENSHOP in exchange for rewards

Value appreciation

SUPPLY REDUCTION

Each redemption permanently reduces the finite token supply, creating inherent scarcity.

RESERVE APPRECIATION

As supply decreases, the Token Reserve represents proportionally higher value per remaining token.

Tokenised rewards program compounds value over time

RWA-Tokenisation

*Launched, validated, and
now in the market*



Xenitra[®]

OPAL Token gaining rapid traction in less than one month

First three weeks: >\$320k in EZZ product sales >56 distributors onboarded

EZZ Life Sciences first brand integrated — \$10m, 4-year global distribution partnership

OPAL token operates on BNB Chain; utility & membership token

Tokens issued via QR code / digital certificate at point of purchase

Reserve fund established from % of sales margins for marketing & rewards

Blockchain-enabled authenticity assurance and loyalty incentives

High-margin tokenised sales = to exceed initial partnership value

OPAL Token Launched and Key General Manager On Board



Capital Raising

Up to \$1.50m Placement at \$0.003 with free attaching 1:2 Options exercisable at \$0.004

XEN Current Capital Structure

XEN Current Ordinary Shares Outstanding	3,862,858,827
Market Capitalisation @ Current Market Price (\$0.004)	\$15,451,435
Cash and Equivalents (31 March 2026)	\$1,830,000
Debt	\$1,000,000
Current Enterprise Value @ Current Market Price (\$0.004)	\$14,621,435

Proposed Issue

Proposed Ordinary Shares	500,000,000
Proposed 1:2 Options	250,000,000
Proposed Broker Shares	15,000,000
Proposed Broker Options	30,000,000

Pro-Forma Capital Structure


Pro-Forma total Ordinary Shares	4,377,858,827
Pro-Forma Market Capitalisation @ Offer Price (\$0.003)	\$13,133,576
Cash and Equivalents (after the raising before cost)	\$3,330,000
Debt	\$1,000,000
Pro-Forma Enterprise Value @ Offer Price (\$0.003)	\$10,803,576

Options & Performance Rights

XEN Current Options - Various Expiries (listed & unlisted)	1,999,785,358
Proposed 1:2 Options exercisable at \$0.004 each on or before 2 April 2028	250,000,000
Proposed Broker Options	30,000,000

Xenitra®

Experienced Board and Senior Management Team



Dr Anthony Noble
Non-Executive Chairman
Doctor of Philosophy, Master of Business Administration, Bachelor of Science

Anthony has extensive Board and management experience, including as CEO and Managing Director of Australian Biotherapeutics and The Calmer Co. Anthony worked for a decade building SFI-Health Group as Group Head of Innovation, Group Head of North Asia and was Managing Director of SFI-Research and SFI-Shineway (China). Anthony was part of the M&A team which acquired and integrated multiple companies including Flordis (Australia) Ginsana (Switzerland), Klair Labs (USA), Prothera (USA), Complementary Prescriptions, (USA) and Potters (UK). Anthony is Executive Director at Servatus Biopharmaceuticals Limited and leads their fast-growing Biomiq skincare brand.



Ms Zhao (Tracy) Zhang
Head of China
Bachelor of Information Technology and Master of Accounting

Tracy is the commercial leader of Xenitra globally and is an accomplished professional in the Fast-Moving Consumer Goods (FMCG) sector. Throughout her career she has developed exceptional expertise in brand management, ecommerce and commercial operations. She is the architect behind the Hui Beijia brand in China, successfully establishing a thriving network of over 400 stores nationwide and since 2023 has spearheaded significant commercial expansion within the Xenitra Sales and Marketing ecosystems in the Chinese market and internationally.




Mr Carl Hagon
Non-Executive Director
Bachelor of Laws, Bachelor of Arts

Carl is an experienced board director with a strong background in governance, strategy, and commercial leadership. He brings a disciplined, outcomes-focused approach to board oversight, informed by both senior commercial experience and a foundation in legal practice. In his legal career, Carl has advised clients across multiple sectors, working closely with executive teams on strategy formulation, business transformation, and growth initiatives.



Mr Zoran Grujic
Non-Executive Director
Bachelor of Commerce, Chartered Accountant

Mr Grujic is an accomplished board member and senior finance executive with over 20 years' experience across ASX-listed entities and high-growth organisations. A Chartered Accountant and Graduate of the Governance Institute, he has held senior leadership roles across a diverse range of sectors, including financial services, FMCG, transport, equity markets, NDIS, not-for-profit organisations and SaaS Technology.



Mr Li (Alex) Li
Non-Executive Director
Bachelor of Tourism Management

Alex is a significant figure in international tourism. Founder of VTour Travel the biggest outbound travel wholesaler to Australia. His "Sunny Australia Vision" platform annually sends 25,000 tourists to Australia, while Grand Aust. International brings over 60,000 visitors each year. Chairman & Co-Founder of Queensland Tourism Group & Grand Aust. International P/L AU&NZ and Founder & President of VTour Travel Zhejiang Co. Ltd



Mr Peng Man
General Manager OTC Medicines
Bachelor of Chinese Materia Medica

Ms Peng is an experienced pharmaceutical commercial manager with 11 years' sales and e-commerce in OTC medicines, healthcare and cross-border pharmaceutical channels. He has held senior roles with JD Health International, Harbin Pharmaceutical, Jiuzhou Tong and Beijing Haoyaoshi Pharmacy, managing major platforms including Ali Health, JD Pharmacy, Douyin Healthcare and B2B pharmacy channels. His experience includes supply chain management, pricing, promotions, regulatory, procurement, supplier management and data-led GMV growth, making him well suited to lead the company's OTC medicine business unit.



Mr Double Chen
General Manager, Tokenisation

Mr Chen is an experienced Web3 and digital assets executive with more than 10 years' experience across blockchain, exchange operations, token economics and digital commercial models. An early Bitcoin market participant since 2015, he has worked across multiple digital asset cycles and has deep practical knowledge of token value creation, liquidity and market structure. He has helped develop consumption-linked digital asset models with early RWA characteristics, led global market operations for UKEX, founded Web3 investment firm SilverRock Capital, and is currently focused on building scalable RWA platforms that connect real commercial activity, cashflows and digital assets.



Mr Ming Ye
General Manager OTC Hospital Wholesale

Mr Ye is a senior pharmaceutical and healthcare executive with extensive experience across hospital channel development, pharmaceutical distribution, medical testing and biomedicine services. He has held senior roles with Nanjing Jintongxiang Biotechnology, Nanjing Danzhuanghua Biotechnology and Nanjing Guosheng Pharmaceutical (Sinopharm Group). He has built cooperation with major Class III Grade A hospitals, developed pharmaceutical retail networks and led market expansion teams, bringing strong hospital relationships, wholesale channel expertise and execution capability to the company's OTC medicine strategy.

Key Takeaways

- Xenitra has the strongest established channel to market in China of any Australian listed entity with \$39m in Sales in FY25 and more than \$70m in sales since 2024.
- Rebranded company with a new and focused strategy driving high margin growth.
- Whole company streamlined yielding significant cost savings of over \$1m that will be reflected in all future results.
- Nutritionals business back at historical highs and new \$30m contract in place with meaningfully lower cost base.
- Exciting new OTC Medicine business initiated through acquisition of HK pharmacy - the new opportunity in China like the previous daigou business but with much higher margins and growth potential.
- Global first mover advantage in RWA-Tokenised sales ecosystem, now showing explosive growth:
 - OPAL Token minted and Xen Shop Web3 store built,
 - 56 Distributors onboarded in the first three weeks,
 - \$320k of EZZ product sales now tokenized,
 - IP developed on in the blockchain ecosystem, and
 - Platform highly scalable to new brands and products.

Xenitra[®]